BioNTech

GSK discontinued its HSV therapeutic vaccine, GSK3943104, after a Phase I/II trial failure, highlighting challenges in developing a vaccine for genital herpes. Moderna and BioNTech are now leading contenders with mRNA-based HSV vaccine candidates in development.

Vaccine manufacturing is critical for future pandemic preparedness, requiring global collaboration and optimized processes. Inequitable distribution of COVID-19 vaccines highlights the need for manufacturing in low- and middle-income countries. Challenges include diverse vaccine platforms and regional infrastructure differences, necessitating significant process optimization. Collaborative efforts like BioNTech/CEPI in Rwanda aim to address these issues.

The article discusses the implementation of SSR (Server-Side Rendering) service entry, identified by the data-ssr-entry attribute, within a web page's body element.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Pfizer and BioNTech's Omicron KP.2-adapted Covid-19 vaccine recommended for EU authorization, pending EC decision. The vaccine targets multiple Omicron sublineages, including KP.2, LB.1, KP.3, and KP.3.1.1, showing improved response over previous versions. US FDA approved the KP.2-adapted vaccine for ages 12+, with EUA for ages 6 months to 11 years.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience.

Pfizer and BioNTech announced CHMP's recommendation for marketing authorization of their Omicron KP.2-adapted COVID-19 vaccine for individuals 6 months and older, pending EC review. The vaccine shows improved response against multiple Omicron JN.1 sublineages, similar to the previously authorized JN.1-adapted vaccine. Doses will ship to EU member states upon EC authorization.

BioNTech SE and Pfizer received a positive recommendation from the European Medicines Agency for their Omicron KP.2-adapted COVID-19 vaccine, set for EU authorization for ages 6 months and up. The vaccine promises enhanced efficacy against several Omicron sublineages, with immediate EU distribution upon approval.

WHO declared mpox a PHEIC in 2024, emphasizing the need for more vaccines, especially in Africa. Ongoing trials include Moderna's mRNA-1769 and BioNTech's BNT166a, both in Phase I/II. Bavarian Nordic's Jynneos is also being tested in pediatric patients in the Democratic Republic of Congo.